Eizric et al., 1986 - Google Patents
1, 10 phenanthroline, a metal chelator, protects against alloxan-but not streptozotocin-induced diabetesEizric et al., 1986
- Document ID
- 266612400459679474
- Author
- Eizric D
- de Lúcio M
- Boschero A
- Hoffmann M
- Publication year
- Publication venue
- Journal of free radicals in biology & medicine
External Links
Snippet
Abstract The iron chelator, 1, 10-phenanthroline (Phen), which inhibits hydroxyl radical formation, was tested in vitro and in vivo against alloxan and streptozotocin (STZ) cytotoxicity. Phen injection reduced the severity of alloxan-induced diabetes in rats and …
- 229960001052 Streptozocin 0 title abstract description 43
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5827880A (en) | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease | |
US6573257B2 (en) | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease | |
Yoshihiko | Inhibition of superoxide anion production in macrophages by anti-inflammatory drugs | |
Bertrand | Iron accumulation, glutathione depletion, and lipid peroxidation must occur simultaneously during ferroptosis and are mutually amplifying events | |
Starke et al. | Ferric iron and superoxide ions are required for the killing of cultured hepatocytes by hydrogen peroxide. Evidence for the participation of hydroxyl radicals formed by an iron-catalyzed Haber-Weiss reaction. | |
Jörns et al. | Effect of superoxide dismutase, catalase, chelating agents, and free radical scavengers on the toxicity of alloxan to isolated pancreatic islets in vitro | |
Heikkila et al. | Alloxan-induced diabetes—evidence for hydroxyl radical as a cytotoxic intermediate | |
Lee et al. | Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo | |
Brent et al. | Role of free radicals in toxic hepatic injury II. Are free radicals the cause of toxin-induced liver injury? | |
Volk et al. | Endothelial damage induced by nitric oxide: synergism with reactive oxygen species | |
Simbula et al. | Two mechanisms by which ATP depletion potentiates induction of the mitochondrial permeability transition | |
WO1994013300A9 (en) | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease | |
El-Sayed et al. | Protective effect of captopril against cisplatin-induced nephrotoxicity in rats. | |
US7582786B2 (en) | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease | |
Rauscher et al. | Effects of isoeugenol on oxidative stress pathways in normal and streptozotocin‐induced diabetic rats | |
Maritim et al. | Effects of melatonin on oxidative stress in streptozotocin-induced diabetic rats | |
Vásquez-Vivar et al. | Oxidative activity of primaquine metabolites on rat erythrocytes in vitro and in vivo | |
Sanz et al. | Acute mitochondrial actions of glitazones on the liver: a crucial parameter for their antidiabetic properties | |
Eizric et al. | 1, 10 phenanthroline, a metal chelator, protects against alloxan-but not streptozotocin-induced diabetes | |
Moore et al. | Menadione (2-methyl-1, 4-naphthoquinone)-induced Ca2+ release from rat-liver mitochondria is caused by NAD (P) H oxidation | |
Zhu et al. | Copper-mediated toxicity of 2, 4, 5-trichlorophenol: biphasic effect of the copper (I)-specific chelator neocuproine | |
Eteng et al. | Morin mitigate diethyl phthalate and bisphenol s–Induced hematotoxicity in rats model by abrogating oxidative stress | |
Colotta et al. | Rapid killing of actinomycin D-treated tumor cells by human monocytes. II. Cytotoxicity is independent of secretion of reactive oxygen intermediates and is suppressed by protease inhibitors. | |
Chan et al. | The effect of streptozocin-induced diabetes on the plasma membrane calcium uptake activity of rat liver | |
Linas et al. | Endothelial cells protect vascular smooth muscle cells from H2O2 attack |